Effect of SX-3228, a selective ligand for the BZ1 receptor, on sleep and waking during the light-dark cycle in the rat

The effects of the benzodiazepine1 (BZ1) receptor agonist SX-3228 were studied in rats (N = 12) implanted for chronic sleep procedures. Administration of 0.5, 1.0 and 2.5 mg/kg SX-3228, sc, to rats 1 h after the beginning of the light phase of the light-dark cycle induced a significant reduction of rapid-eye-movement sleep (REMS) during the third recording hour. Moreover, slow wave sleep (SWS) was increased during the fourth recording hour after the two largest doses of the compound. Administration of 0.5, 1.0 and 2.5 mg/kg SX-3228 one hour after the beginning of the dark period of the light-dark cycle caused a significant and maintained (6-h recording period) reduction of waking (W), whereas SWS and light sleep (LS) were increased. REMS values tended to increase during the entire recording period; however, the increase was statistically significant only for the 1.0 mg/kg dose during the first recording hour. In addition, a significant and dose-related increase of power density in the delta and the theta regions was found during nonREM sleep (LS and SWS) in the dark period. Our results indicate that SX-3228 is a potent hypnotic when given to the rat during the dark period of the light-dark cycle. Moreover, the sleep induced by SX-3228 during the dark phase closely resembles the physiological sleep of the rat

Tratamiento farmacológico del insomnio con benzodiazepínicos: cuándo? cuál? durante cuánto tiempo? / Pharmacological treatment of insomnia with benzodiazepines: when? which? low long?

Se analizan a) el ciclo sueño normal, con sus distintas etapas b) el Síntoma de Insomnio y su vincula-a distintas situaciones clínicas (trast. emocionales, afecciones siquiátricas, Psicosis, drogas, alcoholismo, trastornos respiratorios, mioclonias nocturnas, etc.). c) las medidas terapéuticas generales y sicoterapéuticas. d) El tratamiento farmacológico, en especial referencia a los hipnóticos benzodiazepínicos), detallando, la oportunidad de su indicación y las situaciones clínicas en que están contraindicados

Fasciitis proliferativa. / Proliferative fasciitis

Se destacan las caracteristicas de la fasciitis proliferativa en cuanto a su topografia y su histopatologia, relatandose las diferencias con la fasciitis nodular y la miositis proliferativa. Se hace notar la benignidad de los tres procesos y propone no confundirlo con un sarcoma. Se presenta el caso de un paciente de 44 anos de edad, de sexo masculino que presentaba fasciitis proliferativa